USV
Biosimilar developer, India. 3 development products across 3 molecules: pegfilgrastim, somatropin, teriparatide.
About USV
USV holds Indian permissions for three biosimilars, teriparatide in 2012, somatropin in 2013 and pegfilgrastim in 2019, and imports interferon alfa-2b. All of its products are Indian.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Pegfilgrastim | USV pegfilgrastim | · | · | · | · | · | Sep 2019 | · | 1/7 |
| Somatropin | USV somatropin | · | · | · | · | · | Jun 2013 | · | 1/7 |
| Teriparatide | USV teriparatide | · | · | · | · | · | Aug 2012 | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which USV is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Interferon alfa-2b | USV (INN only) | CDSCO | USV Ltd | Sep 2009 | Not stated in the CDSCO list |
Companies on the same molecules
Developers whose portfolios overlap most with USV, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- CDSCOAug 2012USV (INN only), teriparatide
- CDSCOJun 2013USV (INN only), somatropin
- CDSCOSep 2019USV Private (INN only), pegfilgrastim
Compare USV with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant